

REMARKS

The specification has been amended in order to update the cross-reference to related application information.

Claims 2-17 which are directed to the subject matter, which was elected for prosecution and allowed in U.S. application Serial Nos. 09/423,884 and 10/044,223, have been cancelled. Claim 18 has been cancelled and replaced by amended Claim 1.

Claims 1 and 19 are amended to put them in appropriate U.S. claim format. Claim 1 corresponds to Claim 18 written in independent form.

New Claims 20 and 21 are added. Claims 20 and 21 are drawn, respectively, to a pharmaceutical composition and a method of use of the compounds of Claim 19.

No new matter is introduced by the foregoing amendments.

Claims 1 and 19-21 are in the application as amended.

Respectfully submitted,

Dated: 2/5/04



PAUL E. DUPONT

Registration No. 27,438

Address:
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Tel.: (610) 889-6338
Fax: (610) 889-8799